Business
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥ 6 monthsManageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolutionPivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with
About this update from Lyell Immunopharma, Inc.
[{"type":"image","alt":"Lyell Immunopharma, Inc","displaySize":"","headline":null,"caption":"Lyell Immunopharma, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":222,"url":"https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gyyLnTdzLBmCtbGQjs4MFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d","width":300,"height":222}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"71% of patients with complete response remained in complete response at ≥ 6 months","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Manageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolution","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"Pivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with large B-cell lymphoma treated in the third- or later-line setting","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Lyell to host an investor webcast at 8:00 AM ET today","length":53,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":618,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced positive new clinical data from the multi-center Phase 1/2 trial of LYL314, including data from patients with large B-cell lymphoma (LBCL) treated in the third- or later-line (3L+) setting. LYL314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate with Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA that is in development for patients with relapsed and/or refractory (R/R) LBCL. In patients treated in the 3L+ setting (N = 25), LYL314 continued to demonstrate robust clinical responses, wit...